International collaboration is vital to conquering Alzheimer’s disease. At our recent event, U.S. and Dutch researchers exchanged promising ideas and heard from the leaders who are shaping solutions in each of our countries.
With the help of BrightFocus funding, Beatrice Yue, PhD, and colleagues have demonstrated that mutant forms of optineurin are associated with normal tension glaucoma (NTG) through a breakdown of the cell recycling machinery for protein (autophagy).
In two studies receiving international attention, 2013-16 BrightFocus grantee Rik Ossenkoppele, PhD, of Vrije Universiteit (VU) Medical Center, Amsterdam, and colleagues in the Netherlands have lent confidence to our understanding of how Alzheimer’s develops. Their findings help confirm that amyloid beta (Aβ) peptide levels start to build up and aggregate long before Alzheimer’s symptoms develop, and are predictive of disease.
After years spent researching a protein linked to inherited forms of glaucoma, Raquel Lieberman, PhD, and her team at Georgia Tech have provided a three-dimensional view of that protein and a better understanding of what can happen when it becomes misshapen through genetic miscoding.
Last week, researchers in Iceland announced the completion of a large project to sequence the genomes (or complete DNA) of 2,636 of their fellow countrymen. The Icelandic data base is being called a “treasure trove” of information that will further scientists’ understanding of diseases that are not caused by one single genetic mutation, but instead to mutations on several different genes.
In his blog posted on March 17, National Institutes of Health Director Francis Collins asks a provocative question: “What Makes Our Brains Human?” He then provides at least a partial answer to that question with the help of some new science out of Yale.
March 19, 2015
Donate to Cure Brain and Eye Diseases
Help end Alzheimer's, Macular Degeneration, and Glaucoma